Medexus Pharmaceuticals Inc is seeing a notable rise in its stock price, reflecting investor optimism around its recent performance and strategic initiatives.
On the TSX, Medexus Pharmaceuticals Inc (MDP.TO) saw its stock price increase by 2.96% in the last trading session, closing at CA$4.17. This uptick comes amid positive developments for the company, especially regarding its flagship product, GRAFAPEX.
Investor takeaway: Investors may find Medexus an attractive opportunity as the company demonstrates strong product performance and strategic initiatives aimed at enhancing shareholder value.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$160.84M
52W high
$5.25
52W low
$2.47
1W change
+3.85%
Beta
1.81
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 32.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+32.7% Upside
Current Price
C$5.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
52.3%
Annualized
90-Day Vol
45.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.13
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.44 | C$4.55 โ C$6.52 |
| 60 trading days | C$5.78 | C$4.48 โ C$7.46 |
| 90 trading days | C$6.13 | C$4.49 โ C$8.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medexus Pharmaceuticals Inc stock rises 2.96% today
The stock's increase reflects a market capitalization of approximately CA$131.8 million, indicating investor confidence in the company's growth potential.
Bull case
Medexus recently reported a significant increase in demand for GRAFAPEX, with net revenues reaching CA$3.1 million in the recent fiscal Q3 2026 results. This strong performance suggests that the company is growing its market presence and has potential for future revenue growth.
Bear case
Despite the positive movement, Medexus's profit margin remains negative at -0.0027, which indicates ongoing challenges in achieving profitability. Investors should remain cautious about the company's financial health and market volatility.
Advertisement
